Neutralizing monoclonal antibodies against hepatitis C Virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step

Michelle C. Sabo, Vincent C. Luca, Jannick Prentoe, Sharon E. Hopcraft, Keril J. Blight, Min Kyung Yi, Stanley M. Lemon, Jonathan K. Ball, Jens Bukh, Matthew J. Evans, Daved H. Fremont, Michael S. Diamond

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

The E2 glycoprotein of hepatitis C virus (HCV) mediates viral attachment and entry into target hepatocytes and elicits neutralizing antibodies in infected patients. To characterize the structural and functional basis of HCV neutralization, we generated a novel panel of 78 monoclonal antibodies (MAbs) against E2 proteins from genotype 1a and 2a HCV strains. Using high-throughput focus-forming reduction or luciferase-based neutralization assays with chimeric infectious HCV containing structural proteins from both genotypes, we defined eight MAbs that significantly inhibited infection of the homologous HCV strain in cell culture. Two of these bound E2 proteins from strains representative of HCV genotypes 1 to 6, and one of these MAbs, H77.39, neutralized infection of strains from five of these genotypes. The three most potent neutralizing MAbs in our panel, H77.16, H77.39, and J6.36, inhibited infection at an early postattachment step. Receptor binding studies demonstrated that H77.39 inhibited binding of soluble E2 protein to both CD81 and SR-B1, J6.36 blocked attachment to SR-B1 and modestly reduced binding to CD81, and H77.16 blocked attachment to SR-B1 only. Using yeast surface display, we localized epitopes for the neutralizing MAbs on the E2 protein. Two of the strongly inhibitory MAbs, H77.16 and J6.36, showed markedly reduced binding when amino acids within hypervariable region 1 (HVR1) and at sites Universal-GreekwithMathPi.-1.H11011100 to 200 residues away were changed, suggesting binding to a discontinuous epitope. Collectively, these studies help to define the structural and functional complexity of antibodies against HCV E2 protein with neutralizing potential.

Original languageEnglish (US)
Pages (from-to)7005-7019
Number of pages15
JournalJournal of Virology
Volume85
Issue number14
DOIs
StatePublished - Jul 2011

Fingerprint

Hepatitis C virus
Neutralizing Antibodies
neutralizing antibodies
Hepacivirus
epitopes
Epitopes
monoclonal antibodies
Monoclonal Antibodies
Infection
Genotype
infection
Proteins
proteins
genotype
neutralization tests
Hepatovirus
Viral Structural Proteins
Hepatitis C Antibodies
hepatitis A
Luciferases

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Neutralizing monoclonal antibodies against hepatitis C Virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. / Sabo, Michelle C.; Luca, Vincent C.; Prentoe, Jannick; Hopcraft, Sharon E.; Blight, Keril J.; Yi, Min Kyung; Lemon, Stanley M.; Ball, Jonathan K.; Bukh, Jens; Evans, Matthew J.; Fremont, Daved H.; Diamond, Michael S.

In: Journal of Virology, Vol. 85, No. 14, 07.2011, p. 7005-7019.

Research output: Contribution to journalArticle

Sabo, MC, Luca, VC, Prentoe, J, Hopcraft, SE, Blight, KJ, Yi, MK, Lemon, SM, Ball, JK, Bukh, J, Evans, MJ, Fremont, DH & Diamond, MS 2011, 'Neutralizing monoclonal antibodies against hepatitis C Virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step', Journal of Virology, vol. 85, no. 14, pp. 7005-7019. https://doi.org/10.1128/JVI.00586-11
Sabo, Michelle C. ; Luca, Vincent C. ; Prentoe, Jannick ; Hopcraft, Sharon E. ; Blight, Keril J. ; Yi, Min Kyung ; Lemon, Stanley M. ; Ball, Jonathan K. ; Bukh, Jens ; Evans, Matthew J. ; Fremont, Daved H. ; Diamond, Michael S. / Neutralizing monoclonal antibodies against hepatitis C Virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. In: Journal of Virology. 2011 ; Vol. 85, No. 14. pp. 7005-7019.
@article{ec59440c3abe4a92a2f4e14ddc61b5de,
title = "Neutralizing monoclonal antibodies against hepatitis C Virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step",
abstract = "The E2 glycoprotein of hepatitis C virus (HCV) mediates viral attachment and entry into target hepatocytes and elicits neutralizing antibodies in infected patients. To characterize the structural and functional basis of HCV neutralization, we generated a novel panel of 78 monoclonal antibodies (MAbs) against E2 proteins from genotype 1a and 2a HCV strains. Using high-throughput focus-forming reduction or luciferase-based neutralization assays with chimeric infectious HCV containing structural proteins from both genotypes, we defined eight MAbs that significantly inhibited infection of the homologous HCV strain in cell culture. Two of these bound E2 proteins from strains representative of HCV genotypes 1 to 6, and one of these MAbs, H77.39, neutralized infection of strains from five of these genotypes. The three most potent neutralizing MAbs in our panel, H77.16, H77.39, and J6.36, inhibited infection at an early postattachment step. Receptor binding studies demonstrated that H77.39 inhibited binding of soluble E2 protein to both CD81 and SR-B1, J6.36 blocked attachment to SR-B1 and modestly reduced binding to CD81, and H77.16 blocked attachment to SR-B1 only. Using yeast surface display, we localized epitopes for the neutralizing MAbs on the E2 protein. Two of the strongly inhibitory MAbs, H77.16 and J6.36, showed markedly reduced binding when amino acids within hypervariable region 1 (HVR1) and at sites Universal-GreekwithMathPi.-1.H11011100 to 200 residues away were changed, suggesting binding to a discontinuous epitope. Collectively, these studies help to define the structural and functional complexity of antibodies against HCV E2 protein with neutralizing potential.",
author = "Sabo, {Michelle C.} and Luca, {Vincent C.} and Jannick Prentoe and Hopcraft, {Sharon E.} and Blight, {Keril J.} and Yi, {Min Kyung} and Lemon, {Stanley M.} and Ball, {Jonathan K.} and Jens Bukh and Evans, {Matthew J.} and Fremont, {Daved H.} and Diamond, {Michael S.}",
year = "2011",
month = "7",
doi = "10.1128/JVI.00586-11",
language = "English (US)",
volume = "85",
pages = "7005--7019",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "14",

}

TY - JOUR

T1 - Neutralizing monoclonal antibodies against hepatitis C Virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step

AU - Sabo, Michelle C.

AU - Luca, Vincent C.

AU - Prentoe, Jannick

AU - Hopcraft, Sharon E.

AU - Blight, Keril J.

AU - Yi, Min Kyung

AU - Lemon, Stanley M.

AU - Ball, Jonathan K.

AU - Bukh, Jens

AU - Evans, Matthew J.

AU - Fremont, Daved H.

AU - Diamond, Michael S.

PY - 2011/7

Y1 - 2011/7

N2 - The E2 glycoprotein of hepatitis C virus (HCV) mediates viral attachment and entry into target hepatocytes and elicits neutralizing antibodies in infected patients. To characterize the structural and functional basis of HCV neutralization, we generated a novel panel of 78 monoclonal antibodies (MAbs) against E2 proteins from genotype 1a and 2a HCV strains. Using high-throughput focus-forming reduction or luciferase-based neutralization assays with chimeric infectious HCV containing structural proteins from both genotypes, we defined eight MAbs that significantly inhibited infection of the homologous HCV strain in cell culture. Two of these bound E2 proteins from strains representative of HCV genotypes 1 to 6, and one of these MAbs, H77.39, neutralized infection of strains from five of these genotypes. The three most potent neutralizing MAbs in our panel, H77.16, H77.39, and J6.36, inhibited infection at an early postattachment step. Receptor binding studies demonstrated that H77.39 inhibited binding of soluble E2 protein to both CD81 and SR-B1, J6.36 blocked attachment to SR-B1 and modestly reduced binding to CD81, and H77.16 blocked attachment to SR-B1 only. Using yeast surface display, we localized epitopes for the neutralizing MAbs on the E2 protein. Two of the strongly inhibitory MAbs, H77.16 and J6.36, showed markedly reduced binding when amino acids within hypervariable region 1 (HVR1) and at sites Universal-GreekwithMathPi.-1.H11011100 to 200 residues away were changed, suggesting binding to a discontinuous epitope. Collectively, these studies help to define the structural and functional complexity of antibodies against HCV E2 protein with neutralizing potential.

AB - The E2 glycoprotein of hepatitis C virus (HCV) mediates viral attachment and entry into target hepatocytes and elicits neutralizing antibodies in infected patients. To characterize the structural and functional basis of HCV neutralization, we generated a novel panel of 78 monoclonal antibodies (MAbs) against E2 proteins from genotype 1a and 2a HCV strains. Using high-throughput focus-forming reduction or luciferase-based neutralization assays with chimeric infectious HCV containing structural proteins from both genotypes, we defined eight MAbs that significantly inhibited infection of the homologous HCV strain in cell culture. Two of these bound E2 proteins from strains representative of HCV genotypes 1 to 6, and one of these MAbs, H77.39, neutralized infection of strains from five of these genotypes. The three most potent neutralizing MAbs in our panel, H77.16, H77.39, and J6.36, inhibited infection at an early postattachment step. Receptor binding studies demonstrated that H77.39 inhibited binding of soluble E2 protein to both CD81 and SR-B1, J6.36 blocked attachment to SR-B1 and modestly reduced binding to CD81, and H77.16 blocked attachment to SR-B1 only. Using yeast surface display, we localized epitopes for the neutralizing MAbs on the E2 protein. Two of the strongly inhibitory MAbs, H77.16 and J6.36, showed markedly reduced binding when amino acids within hypervariable region 1 (HVR1) and at sites Universal-GreekwithMathPi.-1.H11011100 to 200 residues away were changed, suggesting binding to a discontinuous epitope. Collectively, these studies help to define the structural and functional complexity of antibodies against HCV E2 protein with neutralizing potential.

UR - http://www.scopus.com/inward/record.url?scp=79960485199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960485199&partnerID=8YFLogxK

U2 - 10.1128/JVI.00586-11

DO - 10.1128/JVI.00586-11

M3 - Article

VL - 85

SP - 7005

EP - 7019

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 14

ER -